SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 173345.
  • 2
    Liaw YF, Tsai SL. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Viral Hep. Rev. 1997; 3: 14354.
  • 3
    Liaw YF. Acute exacerbation and superinfection in patients with chronic viral hepatitis. J. Formos. Med. Assoc. 1995; 94: 5218.
  • 4
    Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 11018.
  • 5
    Chu CM, Liaw YF, Sheen IS, Lin DY, ChangChien CS. Chronic hepatitis in Taiwan: II. A clinical and laboratory study. J. Formos. Med. Assoc. 1981; 80: 1193202.
  • 6
    Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, ChangChien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 21619.
  • 7
    Liaw YF, Yang SS, Chen TJ, Chu CM. Acute exacerbation in hepatitis B e antigen-positive chronic type B hepatitis: a clinicopathological study. J. Hepatol. 1985; 1: 22733.
  • 8
    Lok ASF, Lai CL. Acute exacerbation in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J. Hepatol. 1990; 10: 2934.
  • 9
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 122541.
  • 10
    Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody positive patients. Hepatology 1987; 7: 203.
  • 11
    Liaw YF, Pao CC, Chu CM, Sheen IS, Huang MJ. Changes of serum HBV-DNA in two types of clinical events preceding spontaneous HBeAg seroconversion in chronic type B hepatitis. Hepatology 1987; 7: 13.
  • 12
    Liaw YF, Pao CC, Chu CM. Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in a patient with chronic type B hepatitis. Liver 1988; 8: 2315.
  • 13
    Liaw YF, Tai DY, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 1337.
  • 14
    Yang PM, Su IJ, Lai MY et al. Immunohistochemical studies on intrahepatic lymphocyte infiltrates in chronic type B hepatitis, with special emphasis of the activation status of the lymphocytes. Am. J. Gastroenterol. 1988; 83: 94853.
  • 15
    Chu CM, Liaw YF. Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis. Hepatology 1989; 10: 91115.
  • 16
    Chu CM, Shyu WC, Kuo RW, Liaw YF. HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: Its role in the pathogenesis of chronic type B hepatitis. Hepatology 1987; 7: 131116.
  • 17
    Chu CM, Liaw YF. Coexpression of intercellular adhesion molecule-1 and class I major histocompatibility complex antigens on hepatocyte membrane in chronic viral hepatitis. J. Clin. Pathol. 1993; 46: 10048.
  • 18
    Huang SN, Neura AR. Immunohistologic demonstration of hepatitis B viral antigens in liver with reference to its significance in liver injury. Lab. Invest. 1979; 40: 117.
  • 19
    Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection: Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 1987; 92: 2205.
  • 20
    Chu CM, Liaw YF. Immunohistological study of intrahepatic expression of hepatitis B core and e antigen in chronic type B hepatitis. J. Clin. Pathol. 1992; 45: 7915.
  • 21
    Naoumov NV, Portmann BC, Tedder RS et al. Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990; 99: 124853.
  • 22
    Wu PC, Lau JYN, Lau TK et al. Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. Am. J. Clin. Pathol. 1993; 100: 64853.
  • 23
    Chu CM, Yeh CT, Sheen IS, Liaw YF. Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology 1995; 109: 192632.
  • 24
    Chu CM, Liaw YF. Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta superinfection. Gut 1992; 33: 15448.
  • 25
    Hsu YS, Chien RN, Yeh CT et al. Long-term outcome following spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 15227.
  • 26
    Tsai SL, Chen PJ, Lai MY et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J. Clin. Invest. 1992; 89: 8796.
  • 27
    Hsu HY, Chang MH, Hsieh KH et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 7706.
  • 28
    Chisari FV. Viruses, Immunity and Cancer: lessons from hepatitis B. Am. J. Pathol. 2000; 156: 111832.
  • 29
    Liaw YF. Current trends in therapy for chronic viral hepatitis. J. Gastroenterol. Hepatol. 1997; 12 (Suppl.): S34653.
  • 30
    Liaw YF, Chu CM, Huang MJ et al. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis. Liver 1984; 4: 3016.
  • 31
    Perrillo RP. Acute flares in chronic hepatitis B. The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 100922.
  • 32
    Liaw YF. Hepatitis virus under immunosuppressive agents. J. Gastroenterol. Hepatol. 1998; 13: 1420.
  • 33
    Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N. Engl. J. Med. 1990; 323: 295301.
  • 34
    Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B. Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001; 34: 10216.
  • 35
    Chien RN, Liaw YF, Chen TC et al. Efficacy of thymosin a1 in patients with chronic type B hepatitis: a randomized controlled trial. Hepatology 1998; 27: 13837.
  • 36
    Chien RN, Liaw YF, Atkins M, for Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 7704.
  • 37
    Liaw YF, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 38
    Perrillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 18694.
  • 39
    Rossol S, Marinos G, Carucci P, Singet MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 1997; 99: 302533.
  • 40
    Liaw YF, Tsai SL, Chien RN et al. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 6049.
  • 41
    Thomas HC, Waters JA. Future approach to treatment of chronic hepatitis B and hepatitis C infection. J. Viral Hep. 1997; 4 (Suppl.): 927.
  • 42
    Tsai SL, Sheen IS, Chien RN et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C. J. Biomed. Sci. 2003: in press.
  • 43
    Honkoop P, DeMan RA, Niesters HGM et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 6359.
  • 44
    Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 45
    Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): S33337.
  • 46
    Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 56772.
  • 47
    Si Ahmed SN, Tavan D, Pichoud C et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 107888.
  • 48
    Hadziyannis SJ, Papatheodoridis GV, Dimou E et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 49
    Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001; 34: 5839.
  • 50
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 21926.
  • 51
    Laiw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. To continue or not continue lamivudine therapy after emergence of YMDD mutations. Gastroenterology 2002: 122; A628 (Abstract).
  • 52
    Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 131826.
  • 53
    Core Working Party for Asia-Pacific Consensus on hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and C in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000; 15: 82541.